Literature DB >> 19949007

Adjuvant interferon in high-risk melanoma: end of the era?

Filip Janku, Razelle Kurzrock.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2009        PMID： 19949007     DOI： 10.1200/JCO.2009.24.9326

Source DB:  PubMed          Journal:  J Clin Oncol        ISSN： 0732-183X            Impact factor:   44.544


× No keyword cloud information.
  5 in total

1.  Adjuvant interferon alfa for melanoma.

Authors:  Kenneth S Wilson; Andrew Attwell
Journal:  Curr Oncol       Date:  2010-06       Impact factor: 3.677

Review 2.  Immunomodulatory cytokines as therapeutic agents for melanoma.

Authors:  Courtney Nicholas; Gregory B Lesinski
Journal:  Immunotherapy       Date:  2011-05       Impact factor: 4.196

3.  "First do no harm" and the importance of prediction in oncology.

Authors:  Dainius Characiejus; Jasmina Hodzic; John J L Jacobs
Journal:  EPMA J       Date:  2010-07-17       Impact factor: 6.543

4.  U.S. Food and Drug Administration Approval: peginterferon-alfa-2b for the adjuvant treatment of patients with melanoma.

Authors:  Thomas M Herndon; Suzanne G Demko; Xiaoping Jiang; Kun He; Joseph E Gootenberg; Martin H Cohen; Patricia Keegan; Richard Pazdur
Journal:  Oncologist       Date:  2012-09-21

5.  Treatment patterns of adjuvant interferon-α2b for high-risk melanoma: a retrospective study of the Grupo Español Multidisciplinar de Melanoma - Prima study.

Authors:  Enrique Espinosa; Virtudes Soriano; Josep Malvehy; Alfonso Berrocal; Purificación Martínez de Prado; María Quindós; Ainara Soria; Iván Márquez-Rodas; Isabel Palacio; Pablo Cerezuela; Guillermo López-Vivanco; Lorenzo Alonso; Elia Samaniego; Ana Ballesteros; Teresa Puértolas; Rodrigo Díaz-Beveridge; Luis de la Cruz-Merino; Rafael López Castro; Rafael López López; Kendall Stevinson; Patricia Del Barrio; Maria V Tornamira; Vicente Guillém; Salvador Martín-Algarra
Journal:  Melanoma Res       Date:  2016-06       Impact factor: 3.599
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.